BioCatch Raises $10 Million Led by OurCrowd and Blumberg Capital to Fuel Rapid Growth

BOSTON, June 17, 2014 /PRNewswire/ --

BioCatch, the global leader in behavioral biometric authentication and threat detection, announced today that it has completed a $10 million financing round. The funding will be used to expand R&D efforts and continue growth in key markets, including the U.S. and Europe. The financing round was led by venture capital firm Blumberg Capital and equity crowdfunding firm OurCrowd. Existing investors also participated in the funding round.

BioCatch proactively collects and analyses over 400 bio-behavioral, cognitive and physiological parameters to create unique user profiles for visitors to banking and eCommerce sites. BioCatch also significantly reduces friction associated with risky transactions, and then authenticates visitors upon their return to a site as well as identifies users exhibiting behaviors consistent with fraudsters. Enterprises use BioCatch as a tool to improve the employee authentication experience while protecting access to critical IT assets.

"BioCatch's goal is to provide effective fraud protection, while improving user-experience for customers visiting banking and eCommerce sites," said BioCatch CEO Benny Rosenbaum. "This funding will allow us to continue strengthening our offering and expand our global reach in strategic markets, while keeping the world's largest and most influential institutions safe and secure."

Over the last year, the company has seen significant growth and is deployed in numerous banks, eCommerce sites and enterprises around the globe. Leading figures in the authentication and security space including former senior employees of Trusteer, Vasco and RSA have joined BioCatch and share its vision. The company currently employs 20 team members.

BioCatch is easily integrated into existing security structures and works seamlessly with other fraud detection systems. The solution has demonstrated an 80% reduction in false positives for detecting the same amount of fraud, as well as spotted cybercrime activities that other solutions failed to detect such as Remote Access Attacks (RATs) and Malware.

"We are very excited to be partnering with BioCatch and to be part of such a forward-thinking company that helps protect consumers and enterprises from lurking cyber-threats," said Elan Zivotofsky, General Partner at OurCrowd. "With a global network of investors, OurCrowd can help provide BioCatch with a direct line to large potential customers, key industry connections and strategic partners around the world."

As part of the new partnership, Ron Moritz of OurCrowd and Alon Lifshitz of Blumberg Capital will be joining BioCatch's Board of Directors.

About BioCatch  

BioCatch is a leading provider of behavioral authentication and threat detection solutions for mobile and Web applications. Available as a cloud-based solution, BioCatch proactively collects and analyzes more than 400 bio-behavioral, cognitive and physiological parameters to generate a unique user profile. Banks and eCommerce websites and mobile apps use BioCatch to significantly reduce friction associated with risky transactions and protect users against cyber threats, such as Account Takeovers, Man-in-the-Browser (MitB) Malware and Remote Access (RAT) attacks. Additionally, BioCatch provides an enterprise tool that improves the employee authentication experience while protecting access to critical IT assets. The Company was founded in 2011 by experts in neural science research, machine learning and cyber security and is currently deployed in leading banks, eCommerce sites and enterprises across North America, Latin America and Europe. For more information, please visit http://www.biocatch.com.

Media Contact:
Rachel Glaser
GK PR for BioCatch
Rachel@gkipr.com
+972-54-250-9439

SOURCE BioCatch

reade more... Résuméabuiyad

Biometrics Sector Offering Growth Opportunities as Consumers Increasingly Prefer Digital Payment Methods, Opting for Smart Wallets such as Wocket™ and Google Wallet

CORAL SPRINGS, Florida, July 16, 2014 /PRNewswire/ --

Biometrics Companies expand newest smart technology operations as consumers stray from traditional banking methods and convert to digital commerce: NXT-ID, Inc. (OTCBB: NXTD), Verizon Communications Inc. (NYSE: VZ), Google Inc. (NASDAQ: GOOG), eBay Inc. (NASDAQ: EBAY), Apple Inc. (NASDAQ: AAPL) and Blackberry Limited (NASDAQ: BBRY)

NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company focused on the growing m-commerce market, announces the next generation smart wallet, Wocket™ will be "Made in the U.S.A." The first Wockets™ are expected to ship to consumers in September, with advance ordering currently available at http://www.wocketwallet.com. Gino Pereira, CEO of NXT-ID, said, "July is an appropriate time to announce that Wocket will be made in the USA. With most tech companies manufacturing overseas for reasons of economy, we are proud to announce that we will be partnering with MC Assembly to manufacture our biometric smart wallet in Melbourne, FL. We believe some of the highest quality products in the world are made in the USA. We hope to create a win-win situation where we can offer consumers superior product and help to create jobs in the local economy." MC Assembly is a major manufacturing services company with operations in Winchester, Massachusetts, Palm Bay Florida and Zacatecas, Mexico. The company is focused mainly on aerospace, defense, medical, industrial, and niche telecommunications markets.

To read the full press release, please click here: http://www.fnmprofiles.com/profiles-nxtd.html

"MC Assembly is delighted to be selected as NXT-ID's manufacturing partner", said Jake Kulp, Vice President of New Business Development at MC Assembly. "This exciting new product will utilize all of the MC Assembly's leading edge technology manufacturing capital equipment as well as our global supply-chain management and planning tool sets", Mr. Kulp added. "MC Assembly remains committed to the growth of Florida base jobs and serving the high-technology central Florida manufacturing needs like those required by NXT-ID."

Mobile Payment / mCommerce News:  Recently, Verizon (NYSE: VZ) added tablets to its monthly device payment plan, also known as Edge.  With tablets on Edge, you are looking at the same deal as you would get with phones - no upgrade fees, full device value split into 20 equal monthly payments, and the option to upgrade once you have owned the device for 30 days and have have paid off 60% of it. As you can see from the screenshot, devices like the new Sony Xperia Z2 Tablet are already included. Verizon also sells the Galaxy Tab 4, G Pad 8.3, Nexus 7 (2013), Galaxy Note Pro 12.2, and all of the iPads.

Fighting the trend that has seen millennial consumers-those aged 18 to 34-increasingly pulled away from traditional banking channels in favor of all digital methods of storing, moving and using money like Google Wallet (NASDAQ: GOOG) or PayPal (NASDAQ: EBAY);  one Chicago area bank is officially rolling out a digital banking product just for the millennial consumer.  Liberty Bank's new Smart Debit Plus account will gives users access to transfers, electronic statements and text message alerts as well as online bill pay and other money management tools. What it won't come with is checks, as paper checks will not be issues with these accounts, nor will there by a minimum monthly balance or account maintenance fess.  "Since they want to do everything online, we created the account around a first-of-its kind debit card that accesses an array of largely free electronic services," says Kevin Tynan, a marketing executive at the bank, reports Payments Source. http://www.pymnts.com/news/2014/paperless-debit-used-to-lure-millennials/#.U8VRpMJOWHs

Smartphone Technology News: It seems that the Indian smartphone industry will continue to outperform globally. With the introduction of several low-cost smartphones and discounted data tariffs, smartphone shipments in the country surged 244% during fiscal year 2014, according to India-based Manufacturer's Association of Information Technology.  The industry body, going forward, estimates the Indian smartphone industry will double in size during fiscal year 2015; gradually increasing 3G penetration rate and the introduction of next-gen 4G network will compel consumers to upgrade their smartphones. Let's see what Apple (NASDAQ: AAPL), Blackberry (NASDAQ: BBRY) , and Nokia (NYSE: NOK) are doing to capture this explosive expected growth.  Read the full article at http://www.fool.com/investing/general/2014/07/15/apple-blackberry-and-nokia-are-fighting-for-shar-2.aspx

FinancialNewsMedia.com is leading provider of third party publishing & news dissemination services. If you would like more information regarding our news coverage solutions, please visit http://www.financialnewsmedia.com for more details.  Get an edge on the market with our Premium News Alerts that are FREE for a limited time at http://www.financialnewsmedia.com/.  Follow us on Facebook:  http://www.facebook.com/financialnewsmedia and Twitter: http://twitter.com/FNMgroup. 

DISCLAIMER:  FN Media Group LLC (FNMG) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels.  FNMG is NOT affiliated in any manner with any company mentioned herein.  FNMG and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNMG's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities.  The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material.  All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks.  All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release.  FNMG is not liable for any investment decisions by its readers or subscribers.  Investors are cautioned that they may lose all or a portion of their investment when investing in stocks.  For current services performed FNMG has been compensated one thousand four hundred dollars for news coverage of the current press release issued by NXT-ID, Inc. by a non-affiliated third party.

FNMG HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.  

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:
Company:  FN Media Group, LLC
Contact email:  editor@financialnewsmedia.com
U.S. Phone: +1(954)345-0611
URL: http://www.financialnewsmedia.com

SOURCE FN Media Group LLC

reade more... Résuméabuiyad

International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019

DUBLIN, July 11, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019" report to their offering.

http://photos.prnewswire.com/prnh/20130307/600769

The rising number of terror attacks and crimes has created a need for high level security in both private and public sector. Traditional methods used for personnel authentication such as username and passwords, tokens etc. are vulnerable to attacks. Biometrics technology provides high level security and cannot be stolen since it uses an individual's physiological and behavioral characteristics for identification.

The convenience and growing applications in government sector such as national identity schemes, national border control projects such as e-passports among others are the key factors which would help contribute to the growth of biometrics in the upcoming years.

This report analyses the biometrics technology market on a global basis with detailed breakdown into various sub-divisions. It provides cross sectional analysis of the market based on parameters such as geography, application and end use segments. In addition, the analysis provides market estimation in terms of revenue and forecast for the period between 2013 and 2019.

Porter's five forces analysis and value chain analysis included in the report further help in assessing the market situation and competitiveness. Market attractiveness analysis helps to highlight the key industry segments and their comparative attractiveness with other industry segments.

Key Topics Covered:

Chapter 1 Preface

Chapter 2 Executive summary

Chapter 3 Global Biometrics technology market overview

Chapter 4 Global Biometrics technology systems market, by Application Type 2013 - 2019

Chapter 5 Global Biometrics technology market, by End Users 2013 - 2019

Chapter 6 Global Biometrics technology market, by region 2013 - 2019

Chapter 7 Company profiles

Companies Mentioned:

3M Cogent Accu-Time Systems BIO-Key International, Inc. Cognitec Systems, GmbH Daon, Inc. DigitalPersona, Inc. Fujitsu Limited IDTECK, IrisGuard, Inc. Lumidigm, Inc. Morpho SA (Safran) NEC Corporation RCG Holdings, Ltd. Siemens AG Suprema, Inc. For more information visit http://www.researchandmarkets.com/research/3k5x69/biometrics

Media Contact: Laura Wood, +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets

RELATED LINKS
http://www.researchandmarkets.com

reade more... Résuméabuiyad

WaferGen Bio-systems Reports Strong Revenue Growth for Q1 2014

FREMONT, Calif., May 8, 2014 /PRNewswire/ -- WaferGen Bio-systems, Inc. (OTCQB: WGBS) announced today its financial results for the first quarter ended March 31, 2014.

Key Highlights

Revenue for the first quarter of 2014 was $1.4 million, up 687% year over year Revenue for the first quarter of 2014 was 7.7% higher than the total revenue for fiscal year 2013 Net loss for the first quarter of 2014 was $2.5 million, compared to a net loss of $3.8 million in the first quarter of 2013 Cash balance at March 31, 2014 of $6.4 millionTotal revenue for the first quarter of 2014 was $1.4 million, up 687% from $179,000 in the first quarter of 2013.  Net loss for the first quarter of 2014 was $2.5 million, compared to a net loss of $3.8 million in the first quarter of 2013. The net loss reduction was primarily due to an increase in revenue of $1.2 million resulting in an increase in gross profit of $686,000 and a $1.6 million improvement in other income and expenses as a result of reduced interest expense and changes in derivative valuations, offset by a $1.0 million increase in operating expenses.

"We had a strong revenue performance in the first quarter across our product lines with a diverse customer base.  The rapid increase in adoption of our SmartChip platform was augmented by sales of the newly acquired Apollo business," said Ivan Trifunovich, President and CEO of WaferGen.  He added, "As previously disclosed, on January 6, 2014, we acquired substantially all of the assets of IntegenX's product line used in library preparation for NGS, including the Apollo 324TM instrument and PrepXTM reagents, which clearly put us in a strong competitive position.  In fact, the first quarter revenue was almost 8% higher than revenues for all of calendar year 2013, due to higher sales of the Smart Chip products and revenues from the newly acquired product lines.  Another important Q1 milestone was the launch of the SeqReadyTM version of the SmartChip TETM product, which drastically improves throughput and compresses the workflow in NGS sample preparation.  This new product contributed to sales into the clinical NGS market.  We are excited about our progress in the first quarter and we look forward to continuing the momentum as we further execute our growth strategy."

2014 Guidance

Based on our recent results and the successful integration of the IntegenX's product line used in library preparation for NGS, we are increasing the revenue guidance for full year 2014 to be in excess of $6M for 2014 from our prior guidance of in excess of $5 million.  Our net cash use is expected to be $750,000-$800,000 per month.

Investor Conference Call

As previously announced, management will host a conference call and live audio webcast to discuss its financial results for the quarter ended March 31, 2014, today at 5:00 pm ET, 2:00 PT.  Investors are invited to join the webcast and listen to the replay by clicking on the following link: http://public.viavid.com/index.php?id=109116.  In addition, interested parties may listen to the live broadcast by calling (877) 407-3982 for domestic participants and (201) 493-6780 for international participants.

About WaferGen

WaferGen Bio-systems, Inc. is an innovative life science company that offers innovative genomic solutions for clinical testing and research.  The SmartChip MyDesignTM Real-Time PCR System is a high-throughput genetic analysis platform for profiling and validating molecular biomarkers via microRNA and mRNA gene expression profiling, as well as single nucleotide polymorphism (SNP) genotyping.  The SmartChip TETM System is a novel product offering for target enrichment geared towards clinical Next-Gen sequencing (NGS).  The Company now also offers the Apollo 324TM product line used in library preparation for NGS.  These three complementary technologies offer a powerful set of tools enabling more accurate, faster and cheaper genetic analysis based on Next-Gen Sequencing and Real-Time PCR.

For additional information, please see http://www.wafergen.com

Forward Looking Statements

Certain statements made in this press release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended that are intended to be covered by the "safe harbor" created by those sections.  Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms.  Forward-looking statements in this press release may address the following subjects among others: statements regarding the sufficiency of our capital resources, expected operating losses, expected revenues, expected expenses, expected cash usage and our expectations concerning our competitive position and business strategy.  Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q.  We urge you to consider those risks and uncertainties in evaluating our forward-looking statements.  We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made.  Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.

Investor Contacts:

ICR, Inc.
Bob Yedid
bob.yedid@icrinc.com
646-277-1250

Proactive Capital
Jeff Ramson
jramson@proactivecrg.com 
646-863-6893

WaferGen Bio-systems, Inc.
Stephen Baker 
stephen.baker@wafergen.com
510-780-2399

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations (Unaudited)

Gain (loss) on revaluation of derivative liabilities, net

Total other income and (expenses)

Net loss before provision for income taxes

Net loss attributable to common stockholders

Net loss per share - basic and diluted

Shares used to compute net loss per share - basic and diluted

WAFERGEN BIO-SYSTEMS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

Prepaid expenses and other current assets

Liabilities and Stockholders' Equity (Deficit)

Accrued payroll and related costs

Long-term debt, net of discount

Stockholders' equity (deficit):

Preferred Stock: $0.001 par value; 10,000,000 shares authorized; 2,944.7080 shares of Series 1 Convertible Preferred Stock issued and outstanding at March 31, 2014 and December 31, 2013

Common Stock: $0.001 par value; 300,000,000 shares authorized; 9,120,884 and 9,112,559 shares issued and outstanding at March 31, 2014 and December 31, 2013

Total stockholders' equity (deficit)

Total liabilities and stockholders' equity (deficit)

SOURCE WaferGen Bio-systems, Inc.

RELATED LINKS
http://www.wafergen.com

reade more... Résuméabuiyad

Advanced Phase Change Materials - Global Industry Analysis, Size, Share, Growth, Trends and Forecast to 2018

DUBLIN, Feb. 14, 2014 /PRNewswire/ --

Research and Markets

(

http://www.researchandmarkets.com/research/kd3msc/advanced_phase

) has announced the addition of the

"Advanced Phase Change Materials - Global Industry Analysis, Size, Share, Growth, Trends and Forecast to 2018"

report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

Advanced phase change materials (APCMs) are capable of storing and releasing high amounts of energy, whenever these materials change their state. Phase change materials can be segmented into organic, non-organic and bio-based. Increase in total energy supply, growth of construction industry in developed and developing economies and superior heat storage capacity of these materials are a few key drivers which are expected to increase the demand for APCMs. In addition, increasing use of these materials in the textile industry and temperature controlled packaging, coupled with the growth of these industries, is expected to boost the demand over the next few years. However, the high cost and hazardous nature of these materials is expected to hamper the growth of this market. Economic growth in emerging economies of Asia Pacific is expected to open new opportunities for the growth of this market.

Paraffin was the largest product segment of this market accounting for over 50% of the market in 2011. It has high heat storing capacity and is chemically stable in nature. However, other product segments of APCM which include bio-based phase change materials are expected to show the fastest growth within the forecast period. Growing demand for bio-based products is expected to be one of the primary factors expected to drive the demand for other phase change materials. In addition, research and development for this product segment is expected to boost its demand. Other product segment is expected to account for over 13% of the market in 2018.

APCMs in building and construction were the largest application segment within the market accounting for 24% of the market in 2011. Increasing population in large economies such as China, India and U.S. are driving the construction which in turn is expected to fuel the growth of APCM over the next few years. In addition, demand for green construction is expected to contribute to the growth of the market. Shipping and transportation is expected to be the second-fastest growing application segment of phase change materials. Increase trade activities and development of APCMs which enable transportation of perishable goods such as medicines and food is expected to drive the demand in this application segment. Shipping and transportation is expected to account for over 10% of the market in 2018.

Key Topics Covered:

1 Preface

2 Executive Summary

3 Advanced Phase Change Materials: Industry Analysis

4 Advanced Phase Change Materials Market: Product Segment Analysis

5 Advanced Phase Change Materials Market: Application Analysis

6 Advanced Phase Change Materials: Regional Analysis

7 Company Profiles

Companies Mentioned:

Advansa BV BASF Climator Sweden AB Cryopak Dow Building Solutions EI du Pont de Nemours & Company Honeywell International Phase Change Products Pty Ltd (PCP) Rubitherm Technologies GmbH Salca BV For more information visit http://www.researchandmarkets.com/research/kd3msc/advanced_phase

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets

RELATED LINKS
http://www.researchandmarkets.com

reade more... Résuméabuiyad

In Vitro Diagnostics Market - Global Industry Analysis, Size, Share, Growth and Forecast to 2018

DUBLIN, Feb. 14, 2014 /PRNewswire/ --

Research and Markets

(

http://www.researchandmarkets.com/research/ztk89b/in_vitro

) has announced the addition of the

"In Vitro Diagnostics Market - Global Industry Analysis, Size, Share, Growth and Forecast to 2018"

report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769)

In vitro diagnostics provide valuable information regarding the physiological and/or pathological state of the body and therefore are essential in making well-informed medical decisions. This report estimates the market for the in vitro diagnostics terms of revenue (USD million) for the period 2012 - 2018, keeping 2011 as the base year.

The in vitro diagnostics market is segmented by geography and market by products. The market estimation for the U.S. and two emerging economies (China and India) have also been included in the report.

The U.S., India and China in vitro diagnostics market is segmented by products into clinical chemistry IVDs, Immunoassay IVDs, diabetes testing IVDs, blood testing IVDs, molecular diagnostics, and other IVDs. The global market for in vitro diagnostics is segmented on the basis of geography into North America, Europe, Asia-Pacific and rest of the world (RoW) regions and this market is provided in terms of USD million.

This report includes the market shares of key players in 2011. Moreover, company profiles for some of the key players are included in the report in terms of company overview, financial overview, business strategies, recent developments and product portfolio. The major companies included in the report are Abbott Laboratories Inc., Alere Inc., Bayer AG, Becton Dickinson and Company, Biomerieux SA, Beckman Coulter Inc., Danaher Corporation, Gen-Probe Incorporated, Johnson and Johnson, Life Technologies Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthcare (a division of Siemens AG) and Thermo Fisher Scientific Corporation.

Key Topics Covered:

1 Preface

2 Executive Summary

3 Market Overview

4 Global In Vitro Diagnostics Market, by Products (Qualitative information)

5 Global In Vitro Diagnostics Market, by Geography

6 U.S. In Vitro Diagnostics Market, by Products

7 China In Vitro Diagnostics Market, by Products

8 India In Vitro Diagnostics Market, by Products

9 Competitive Landscape

10 Company Profiles

Companies Mentioned:

Abbott Laboratories Inc Alere, Inc Bayer AG Beckman Coulter, Inc Becton, Dickinson and Company Biomerieux SA F Hoffmann-La Roche Ltd Gen-Probe Incorporated Johnson and Johnson Life Technologies Corporation Siemens Healthcare Thermo Fisher Scientific, Inc For more information visit http://www.researchandmarkets.com/research/ztk89b/in_vitro

Media Contact: Laura Wood , +353-1-481-1716, press@researchandmarkets.net

SOURCE Research and Markets

RELATED LINKS
http://www.researchandmarkets.com

reade more... Résuméabuiyad